AngioDynamics and Merz North America establish multi-year relationship to market Asclera for vein patients

321

AngioDynamics has signed an agreement with Merz North America, a US affiliate of the global Merz Pharma Group, to serve as the exclusive distributor of Asclera (polidocanol) injection within the US vein market.

Asclera is approved for the treatment of uncomplicated spider and uncomplicated reticular (small varicose) veins. In a multicentre, randomised, double-blind, placebo and comparator-controlled trial in patients with spider or reticular varicose veins, 95% of patients treated with Asclera showed good improvement or complete treatment success as rated by physicians and 87% of patients were satisfied or very satisfied with their Asclera treatment.